Cascadian Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference

SEATTLE, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. CASC, a clinical-stage biopharmaceutical company, today announced that management will present at the Cowen and Company 37^th Annual Health Care Conference on Monday, March 6, 2017, at 3:20 p.m. Eastern time / 12:20 p.m. Pacific time in Boston.

A live audio webcast of the presentation will be available through the "Events & Presentations" page of the "News & Events" section of Cascadian Therapeutics' website at cascadianrx.com. An archived edition of the session will be available later that day.

About Cascadian Therapeutics

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib (also known as ONT-380) is an oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.clinicaltrials.gov NCT or www.HER2CLIMB.com. For more information, please visit www.cascadianrx.com.

Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
mgreer@cascadianrx.com